`
`Exhibit 8
`
`
`
`Moderna’s Commitment to Patient Access in the United States
`2/27/23, 11:07 AM
`Case 1:22-cv-00252-MSG Document 59-8 Filed 03/02/23 Page 2 of 3 PageID #: 1060
`NASD: MRNA $138.72 Vol: 1,627,893
`
`
`
`
`
`
`
`
`
`
`
`
`
`VIEW ALL NEWS
`
`DOWNLOAD
`
`Moderna’s vaccines have protected the lives of hundreds of millions of people around the world from COVID-19 and have dramatically lessened the burden of
`the pandemic to society.
`
`As the public health emergency ends, the United States government will no longer be providing vaccines at no cost. Moderna remains committed to ensuring
`that people in the United States will have access to our COVID-19 vaccines regardless of ability to pay.
`
`Moderna’s COVID-19 vaccines will continue to be available at no cost for insured people whether they receive them at their doctors’ offices or local pharmacies.
`For uninsured or underinsured people, Moderna’s patient assistance program* will provide COVID-19 vaccines at no cost.
`
`Everyone in the United States will have access to Moderna’s COVID-19 vaccine regardless of their ability to pay.
`
`*Available after the expiry of the COVID-19 Public Health Emergency on May 11, 2023.
`
`VIEW ALL NEWS
`
`Skip to main content
`
`https://investors.modernatx.com/Statements--Perspectives/Statements--Perspectives-Details/2023/Modernas-Commitment-to-Patient-Access-in-the-U… 1/2
`
`MODERNA’S COMMITMENT TO PATIENT ACCESS IN THE UNITED STATES
`02/ 15/2023
`Statements & Perspectives
`Details
`Abou t Us
`The Power Of MRNA
`Research
`Respons ib i l ity
`COV ID -19
`Overv iew News
`Events & Presentat ions
`Stock Info
`F inanc ia ls
`Governance
`Resources
`Statements & Perspect ives
`
`
`Moderna’s Commitment to Patient Access in the United States
`2/27/23, 11:07 AM
`Case 1:22-cv-00252-MSG Document 59-8 Filed 03/02/23 Page 3 of 3 PageID #: 1061
`NASD: MRNA $138.72 Vol: 1,627,893
`
`ir@modernatx.com
`
`Events &
`Presentations
`SEC Filings
`
`Quarterly
`Reports
`End of
`Day
`Stock
`Quote
`
`SEC Filings
`
`Investor
`FAQs
`
`Information
`Request
`Form
`
`Enter yo
`
`News
`
`Annual
`Reports
`
`Unsubscribe
`
`Investor overview
`
`All Media
`
`Company culture
`
`Blogs
`
`People behind the science
`
`Press releases
`
`Media kit
`
`Strategic collaborators
`
`Join our team
`
`New venture labs
`
`Terms of Use
`Moderna
`
`Site Map
`
`Privacy Policy
`
`Contact
`
`© 2023 Moderna, Inc.
`
`https://investors.modernatx.com/Statements--Perspectives/Statements--Perspectives-Details/2023/Modernas-Commitment-to-Patient-Access-in-the-U… 2/2
`
`Quick Links
`IR Contact
`Investor Email Alerts
`SUBMIT
`Investors
`Newsroom
`Media Center
`Partnerships
`Careers
`Innovation Incubator
`Abou t Us
`The Power Of MRNA
`Research
`Respons ib i l ity
`COV ID -19
`Overv iew News
`Events & Presentat ions
`Stock Info
`F inanc ia ls
`Governance
`Resources
`Statements & Perspect ives
`